New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
15:27 EDTSYKMariel Therapeutics to acquire Stryker's BMP-7 assets
Mariel Therapeutics announced that it has entered into a definitive agreement to acquire Stryker Corporation's Bone Morphogenetic Protein-7, or BMP-7, assets for the potential treatment of osteoarthritis, chronic kidney disease and other organ fibrosis conditions, lupus, and obesity. Under the terms of the agreement, Mariel acquired the rights to over 450 issued and pending patents, Stryker's BMP-7-related clinical and research data, and the associated biologic materials. Stryker will have a right of first negotiation for commercial rights in the area of osteoarthritis. Financial terms of the transaction were not disclosed.
News For SYK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2015
16:12 EDTSYKStryker sees FY15 constant currency sales growth 6.5%-7.5%, consensus $9.93B
Subscribe for More Information
16:12 EDTSYKStryker sees Q3 adjusted EPS $1.20-$1.25, consensus $1.20
Subscribe for More Information
16:10 EDTSYKStryker raises FY15 adjusted EPS view to $5.06-$5.12 from $4.95-$5.10
Subscribe for More Information
16:08 EDTSYKStryker reports Q2 adjusted EPS $1.20, consensus $1.17
Subscribe for More Information
15:04 EDTSYKNotable companies reporting after market close
Subscribe for More Information
July 22, 2015
16:22 EDTSYKSynergetics completes early renewal of Stryker supply agreement
Subscribe for More Information
July 20, 2015
08:04 EDTSYKStryker announces definitive agreement tyo acquire Muka Metal
Stryker announced a definitive agreement to acquire Muka Metal, A.S. in an all cash transaction. Muka, headquartered in Kayseri, Turkey, sells hospital beds, stretchers and related patient room furniture and accessories that serve markets across Turkey and other regions globally. Upon closing, the transaction is expected to be neutral to Stryker's FY15 EPS excluding acquisition, integration-related and intangible amortization charges and accretive thereafter. The transaction is expected to close in Q3.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use